Effectiveness of heliotherapy for psoriasis clearance in low and mid-latitudinal regions: A theoretical approach.

21:59 EST 28th February 2015 | BioPortfolio

Summary of "Effectiveness of heliotherapy for psoriasis clearance in low and mid-latitudinal regions: A theoretical approach."

The action spectrum for psoriasis clearance is reconstructed taking into account the results obtained in the early 1980s. The antipsoriatic action spectrum is used for weighting the medical cabinet UV spectra, and the solar spectra measured in San Diego (USA) and Belsk (Poland). The mean cumulative antipsoriatic effective dose of 450mJcm(-2), due to TL-01 (UVB narrowband) tubes, is taken by a patient with skin phototype II during routine 20 phototherapy sessions carried out in a phototherapy cabinet in the Medical University of Łódz. Thus, the daily mean dose of value 22.5mJcm(-2) is proposed as the threshold for daily solar dose for numbers of out-door exposures to clear psoriasis. We assume that the heliotherapy will last a whole month with every day 2h exposition to the direct sunlight around local noon. The heliotherapy will be successful if weather conditions permit at least 20days with the daily exposure over the threshold. The minimum cumulative ambient erythemal dose, necessary for psoriasis clearance, is estimated as 144 standard erythema dose (SED) for the whole heliotherapy period. We find that heliotherapy could be effectively used in March through October (San Diego) and in June through August (Belsk). Thus, the heliotherapy against psoriasis is possible not only at southern resorts but even at the mid-latitude sites.

Affiliation

Institute of Geophysics, Polish Academy of Sciences, Warsaw, Poland.

Journal Details

This article was published in the following journal.

Name: Journal of photochemistry and photobiology. B, Biology
ISSN: 1873-2682
Pages: 35-41

Links

PubMed Articles [17966 Associated PubMed Articles listed on BioPortfolio]

Efficacy of Botulinum Neurotoxin Type A for Treating Recalcitrant Plaque Psoriasis.

Use of botulinum neurotoxin A (BoNTA) for treating inflammatory skin disease is an underexplored area in medical dermatology. Preclinical mouse studies have demonstrated efficacy of abobotulinumtoxinA...

Impact of SPA therapy with sulphureous mineral water on quality of life and psychological distress in chronic plaque psoriasis.

The plaque psoriasis, one of the most common form of psoriasis, is a chronic inflammatory disease. This pathology can cause devastating effects on quality of life and social relations with significant...

Geographic Tongue and Fissured Tongue in 348 Patients with Psoriasis: Correlation with Disease Severity.

Geographic tongue (GT) and fissured tongue (FT) are the more frequent oral lesions in patients with psoriasis. The aims of this study were to compare the prevalence of GT/FT between psoriasis group (P...

Clearance of Psoriasis: The Impact of Private Versus Public Insurance.

Psoriasis treatments and therapeutic response as they relate to private versus public patient insurance in the United States have not yet been reviewed. Improved understanding could clarify factors ch...

Pharmaceuticals and medical technologies may have different outcomes in randomized controlled trials and observational studies. Register-based research can provide complementary information about the ...

Clinical Trials [2166 Associated Clinical Trials listed on BioPortfolio]

Primary UVB-311nm and Adalimumab in Psoriasis Patients

Adalimumab, a fully human anti-tumor necrosis factor (TNF) monoclonal antibody has been approved for the treatment of moderate to severe psoriasis. However, in a portion of cases adalimum...

Narrow-Band UVB-Therapy in Psoriasis

Study on two different irradiation schemes in UVB phototherapy for psoriasis. Previous studies demonstrated a similar clinical effect in erythematogenic and suberythematogenic irradiation,...

UVB-311nm After Initial Slow Response to Adalimumab in Psoriasis

Adalimumab, a fully human anti-tumor necrosis factor (TNF) monoclonal antibody has been approved for the treatment of moderate to severe psoriasis. However, in a portion of cases adalimum...

Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Psoriasis

The current study will compare the real - life effectiveness of adalimumab to topical and traditional systemic agents in the management of psoriasis and its impact on the patient's quality...

A Canadian Open-Label Access Program to Evaluate Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis

To evaluate the safety profile, the effectiveness and the economic impact of adalimumab when used for the treatment of subjects with active plaque psoriasis who have not adequately respond...

Medical and Biotech [MESH] Definitions

Theoretical representations that simulate the behavior or activity of systems, processes, or phenomena. They include the use of mathematical equations, computers, and other electronic equipment.

The treatment of disease by exposing the body to SUNLIGHT, a therapeutic use of SUNBATHING.

A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.

A non-specific host defense mechanism that removes MUCUS and other material from the LUNGS by ciliary and secretory activity of the tracheobronchial submucosal glands. It is measured in vivo as mucus transfer, ciliary beat frequency, and clearance of radioactive tracers.

Any situation where an animal or human is trained to respond differentially to two stimuli (e.g., approach and avoidance) under reward and punishment conditions and subsequently trained under reversed reward values (i.e., the approach which was previously rewarded is punished and vice versa).

Search BioPortfolio:
Loading
Advertisement

Relevant Topic

Alzumab (Itolizumab)
Latest News Clinical Trials Research Drugs Reports Corporate
Biocon Launches ALZUMAb™ - a ‘First in Class’ Novel Biologic Treatment for Psoriasis Patients in India • ALZUMAb™-World's first novel anti-CD6 antibody developed by Biocon to address a large unmet need for th...

Advertisement

Searches Linking to this Article